Cargando…

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

BACKGROUND: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in diverse tumors. To determine the clinical utility of detecting BIM deletion polymorphisms (par4226 bp/ par363 bp) in EGFR positive non-small-cell lung cancer (NSCLC) we examined the outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardona, Andrés F., Rojas, Leonardo, Wills, Beatriz, Arrieta, Oscar, Carranza, Hernán, Vargas, Carlos, Otero, Jorge, Corrales-Rodriguez, Luis, Martín, Claudio, Reguart, Noemí, Archila, Pilar, Rodríguez, July, Cuello, Mauricio, Ortíz, Carlos, Franco, Sandra, Rolfo, Christian, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356601/ https://www.ncbi.nlm.nih.gov/pubmed/27926478 http://dx.doi.org/10.18632/oncotarget.12112

Ejemplares similares

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2020)

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2021)

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
por: Chamorro, Diego F., et al.
Publicado: (2023)

Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2020)

Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2020)

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2019)

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2019)

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC
por: Incharoen, Pimpin, et al.
Publicado: (2019)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
por: Rojas, Leonardo, et al.
Publicado: (2019)

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
por: Raez, Luis E., et al.
Publicado: (2022)

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis
por: Lv, Fangfang, et al.
Publicado: (2021)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
por: Cifuentes, Claudia, et al.
Publicado: (2023)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Epithelial–mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy
por: Rojas‐Puentes, Leonardo, et al.
Publicado: (2016)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
por: Liu, Si‐Yang, et al.
Publicado: (2020)

Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy
por: Raez, Luis E., et al.
Publicado: (2020)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
por: Rodríguez, July, et al.
Publicado: (2021)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis
por: Nie, Wei, et al.
Publicado: (2015)

BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis
por: Su, Wenxia, et al.
Publicado: (2019)

Notch3 Cooperates With the EGFR Pathway to Modulate Apoptosis Through The Induction Of Bim
por: Konishi, Jun, et al.
Publicado: (2009)

Implementation of Space Charge Forces in BimBim
por: Gottlob, Emmanuel
Publicado: (2017)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP‐LATimus)
por: Martín, Claudio, et al.
Publicado: (2021)

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
por: Barrios-Bernal, Pedro, et al.
Publicado: (2022)

BIM Demystified
por: Race, Steve
Publicado: (2019)

Bim Demystified
por: Race, Steve
Publicado: (2012)

BIM Design
por: Garber, Richard
Publicado: (2014)

Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
por: Rojas, L., et al.
Publicado: (2022)

The BIM-manager: a practical guide for BIM project management
por: Baldwin, Mark, et al.
Publicado: (2019)

Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado
por: Cañas, Alejandro, et al.
Publicado: (2022)

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017)

BIM in Small Practices
por: Klaschka, Robert
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dp049v6da44nbla5j1jeajsf9g